An interventional study of Blood test: measurement of plasma antipsychotic concentration and Voice interviews and questionnaires carried out via the CALLYOPE application in Schizophrenia, sponsored by Centre Hospitalier St Anne. Recruiting at 2 sites in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Centre Hospitalier St Anne · Not applicable, Interventional, and Other
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive impairment and social isolation. Treatments with antipsychotics have proven effective in improving their living conditions, but poor compliance results in relapses and rehospitalizations for the majority of patients, which often results in a worsening of residual symptoms. The prevention of these relapses is a major issue in the care of these patients and frequent monitoring is necessary. The use of a simple, rapid and inexpensive tool to monitor symptoms and treatment effect in schizophrenia could improve the effectiveness of the treatment of these patients and prevent relapses. Speech is a good candidate as a biomarker in the monitoring of patients with schizophrenia. Schizophrenia is accompanied by speech disorders including poor speech, variations in tone or intensity or even difficulties in organizing speech.
Schizophrenia is a highly complex disease of unknown origin. It is characterized by a heterogeneous etiology and variable clinical manifestations. Numerous studies have investigated genetic, biochemical or neurodevelopmental factors of the pathology, without providing a definitive answer. The environmental factor is also analyzed, especially urban density and pollution. Finally, the immune pathway, in particular neuroinflammation, has been studied. Certain parasites, such as Toxoplasma, may be involved in the development of schizophrenia in combination with genetic factors. All these studies tend to show that the parasite/gene/environment association would influence the development of schizophrenia, but the origins remain unclear and a more complete knowledge of the pathophysiology is needed to improve diagnosis and patient management through new therapeutic targets.
More than 80% of patients with schizophrenia have language abnormalities. These abnormalities are manifested in syntax, semantics and phonology. The most common include monotonous intonation, poverty of speech, increased pauses, lack of spontaneity, and disruption of speech coherence. As speech is an important factor in social interaction, patients have great difficulty in maintaining their social relationships.
A major problem in schizophrenia is the discontinuation or misuse of antipsychotic treatment, which leads to relapse and additional hospital costs. According to a 2013 study, 50% of patients discontinue treatment after six months, often leading to decompensations.To avoid relapses, clinicans can either administer hetero-questionnaire to monitor the patients' symptoms or monitor treatment adherence.
To monitor symptoms, clinicians have at their disposal various standardized questionnaires such as the PAANS. However, those tests are time-intensive.
To monitor treatment adherence, clinicians can use blood drug concentrations as an evidence of compliance, although this method is invasive, and requires costly administration coordination between healthcare profesionnals and patients. There are also several standardized tests to monitor adherence, such as the clinician-administered BARS questionnaire and the self-administered BEMIB. These measures have often been criticized due to factors such as recall bias and poor self-perception, which limit the accuracy of patient reports and overestimate adherence.
It is therefore essential to develop new tools to objectively measure evolution of symptoms and treatment effects to detect onset of relapses, without increasing the burden on patients' daily lives.
Speech voice markers stand out because they have characteristics that make it easy to use in clinical practice and can be easily integrated into patients' daily lives. Advances in signal processing and machine learning algorithms now make it possible to measure the different components of speech: phonatory skills, articulation, the different linguistic levels (semantics, syntax, morphology, pragmatics) as well as the specific disfluencies of spontaneous speech.
These different speech markers have been validated in different neurological and psychiatric pathologies: in particular, Parkinson's disease, Huntington's disease, depression, suicidal risk, and schizophrenia. These markers of speech in psychiatry are now generalizing across languages and are also being taken into patients' homes to measure changes in patient states.
Distinctive voice characteristics have been a feature of schizophrenia since it was first defined. They are often associated with negative symptoms, such as the inability to show emotion, and with observed social impairments. It has been quantitatively observed that people with schizophrenia have poorer speech, more pauses, distinctive tones, and differences in voice intensity.
Studies have shown antipsychotics also affect language, since patients are dopamine-deficient, and blockade of these receptors by antipsychotics would exacerbate language impairments. In addition, blockade of the striatal dopamine receptor leads to extrapyramidal side effects, causing tremors, muscle rigidity, and tics that interfere with the joint movements required for speech.
Therefore, voice and language are very good candidates as biomarkers in monitoring both symptoms and treatment effects in schizophrenia to detect onsets of relapses.
The aim of this study is to determine whether voice biomarkers can be used to objectively monitor symptoms and treatment effects in schizophrenia in order to detect onset of relapses.
3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.
This study's planned enrollment of 200 is above the median of 71 across 2,944 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Centre Hospitalier St Anne is the lead sponsor of 101 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study's interventions: * 4 blood tests (inclusion visit, at follow-up visits at 2 and 4 months after inclusion, at the end-of-study visit at 6 months after inclusion) to measure the blood concentration of antipsychotic treatment (risperidone or paliperidone) * completion of self-questionnaires and voice interviews of the application developed by CALLYOPE
Biological: Blood test: measurement of plasma antipsychotic concentration · Other: Voice interviews and questionnaires carried out via the CALLYOPE application
Four blood tests are prospectively realized per patient during the study to measure the plasma concentration of antipsychotics (primary treatment: risperidone/paliperidone, olanzapine or aripiprazole). These blood samples are taken at the inclusion visit, at the follow-up visits 2 and 4 months after the inclusion visit, then at the end-of-study visit 6 months after the inclusion visit.
Voice interviews carried out via the Callyope application: they consist of a series of tests, divided into two parts: Structured tasks (same content for each participant) and Semi-structured tasks (content varies for each participant). The simultaneous analysis of several speech tasks allows us to break down the different stages of speech production and the important factors that influence its achievement. In addition, patients will complete self-questionnaires via the application. Finally, lifestyle habits (sleep duration and number of steps) will be recorded via the application. These different tests will be carried out on the application at the inclusion visit (M0), then every month (M1, M2, M3, M4, M5) until the end of study visit (M6).
Voice interviews recorded on Callyope application
The analysis of the interviews (acoustic and linguistic features) will be implemented in a voice model predicting a score.
Time frame: Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6
Plasma concentration of antipsychotics
Plasma concentration of antipsychotics measured in ng/mL from Month 0 to Month 6.
Time frame: Month 0, Month 2, Month 4, Month 6
Age
Age in years
Time frame: Month 0
Weight
Weight in kilograms
Time frame: Month 0
Sex
Sex (Male / Female)
Time frame: Month 0
Change from Baseline in the schizophrenia severity
Schizophrenia severity will be assessed by the investigator with PANSS (Positive and Negative Syndrome Scale) scale. For positive symptoms, score range is 7-49; For negative symptoms, the score range is 16 to 112. Higher score mean a worse outcome.
Time frame: Month 0, Month 2, Month 4, Month 6
Change from Baseline in the schizophrenia severity
Schizophrenia severity will be assessed by the investigator with CGI-SH (Clinical Global Impression - Schizophrenia) scale. Score range (min - max): 0 - 7 for the severity subscale Symptomatic remission correspond to a score ≤3 (CGI-S).
Time frame: Month 0, Month 2, Month 4, Month 6
Changes from Baseline in the schizophrenia severity
Schizophrenia severity will be assessed by the investigator with the scores from MCSI (Modified version of the Colorado Symptom Index) questionnaire. Score range (min-max) : 5-70 Higher score relates to worse outcome
Time frame: Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6
Number of hospitalizations
The total number of schizophrenia-related hospitalizations will be collected by the investigator from enrollment to the end of study at 6 months.
Time frame: From enrollment to the end of study at 6 months
Total sleep duration
The total sleep duration in hours and minutes will be automatically measured by the Callyope application
Time frame: From enrollment to the end of study at 6 months
Duration of daily physical activity
Duration of time spent at home, time in stationary mode in hours and minutes automatically assessed by the Callyope application
Time frame: From enrollment to the end of study at 6 months
Phases of sleep duration
Duration of sleep phases in hours and minutes automatically assessed by the Callyope application
Time frame: From enrollment to the end of study at 6 months
Plasma concentration of sedative antipsychotics
Plasma concentration of sedative antipsychotics measured in ng/mL from Month 0 to Month 6
Time frame: Month 0, Month 2, Month 4, Month 6
Daily travel distance
Maximum daily travel distance from home in kilometers automatically assessed by the Callyope application
Time frame: From enrollment to the end of study at 6 months
Changes from Baseline in the symptoms (Depression, anxiety, functional autonomy, fatigue)
Symptoms will be assessed by the score of the PHQ-9 (Patient Health Questionnaire - 9) questionnaire. Score range (min - max): 0 - 27 Higher score relates to a worse outcome
Time frame: Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6
Changes from Baseline in feelings of loneliness or social isolation
Feelings of loneliness or social isolation will be assessed by the investigator from the Score from UCLA 3-item Loneliness Scale. The total score ranges from 20 to 80. Higher scores indicate higher loneliness.
Time frame: Month 0, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6
Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.
Of 753 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 30 months is close to that.
Counting every sponsor, half of 766 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.